Alaunos Therapeutics (TCRT) Change in Account Payables (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Change in Account Payables came in at -$212000.0 in Q1 2026, down 167.3% YoY from $315000.0 in Q1 2025, and up 7.83% on a QoQ basis from -$230000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Change in Account Payables (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Change in Account Payables data on file, last reported at -$212000.0 in Q1 2026.
- Quarterly Change in Account Payables fell 167.3% year-over-year to -$212000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$430000.0 (down 283.76% YoY) and the FY2025 annual result came in at $97000.0, up 197.0% from the prior year.
- Change in Account Payables rose to -$212000.0 in Q1 2026, from -$230000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.5 million in Q3 2022 to a low of -$763000.0 in Q1 2022.
- A 5-year average of -$59588.2 and a median of -$110000.0 in 2023 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 1757.89% in 2025, down 489.83% in 2025.
- Tracing TCRT's Change in Account Payables over 5 years: stood at -$641000.0 in 2022, then decreased by 6.24% to -$681000.0 in 2023, then jumped by 108.66% to $59000.0 in 2024, then slumped by 489.83% to -$230000.0 in 2025, then rose by 7.83% to -$212000.0 in 2026.
- The last three Change in Account Payables figures came in at -$212000.0 (Q1 2026), -$230000.0 (Q4 2025), and $34000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | 330,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212,000.00 |
| Mar 31, 2026 | -212,000.00 |
| Dec 31, 2025 | -230,000.00 |
| Dec 31, 2025 | -230,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | -22,000.00 |
| Jun 30, 2025 | -22,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Dec 31, 2024 | 59,000.00 |
| Dec 31, 2024 | 59,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | -232,000.00 |
| Jun 30, 2024 | -232,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Dec 31, 2023 | -681,000.00 |
| Dec 31, 2023 | -681,000.00 |